Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Veracyte, Inc.

NASDAQ: VCYT · Industrial Applications and Services · 7 alerts · CIK 1384101

Share price
$24.01Close, Nov 16
Market cap
$1.94B
Shares outstanding
80.7MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Veracyte, Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
M&A Deal

Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.

Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.

Value
$150M
Counterparty
Convergent Genomics Inc.

“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”

Marc Stapley, Veracyte’s chief executive officer

“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”

Brian Slingerland, chief executive officer, Convergent Genomics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.